All News
Less Mortality with GLP-1 Agonists in Rheumatic Patients
A recent article in PLOS ONE has shown that treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory diseases and type 2 diabetes.
Read Article
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients
Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axial spondyloarthritis (axSpA).
Read Article
Lead with Lupus (8.2.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com - leading with lupus because everyone wants to know about lupus!
Read Article
Best Rheumatologists (7.19.2024)
This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.
Read Article
355 PsA (n=279) & psoriasis (76) pts studied. PsA pts had more comorbidity vs PsO (43% v 26%). >70% low exercise level. Exercise signif improved DAPSA, TJC/SJC, ESR, PASI. Hi Mediterranean diet decr ESR, PASI, but signif only for enthesitis (p 0.015) https://t.co/mdruLj9h5a https://t.co/NOiwXju0wm
Dr. John Cush RheumNow ( View Tweet)
Oral microbiota study (w/ 16S rRNA sequencing) of 72 severe psoriasis vs 16 controls. PsA pts had incr in Aggregatibacter & decr Prevotella. PsO pts had incr in Capnocytandophaga, Campylobacter & Acetobacter, but decr Bacteroides & Muribaculaceae https://t.co/ol947Afupt https://t.co/OknMRtJ4oT
Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3
Links:
Dr. John Cush RheumNow ( View Tweet)
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients
Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axSpA.
https://t.co/lVCdGnMVaT https://t.co/jFILeHrQXj
Dr. John Cush RheumNow ( View Tweet)
PROs: Their Proper Place
https://t.co/gYjrRcqLy4 https://t.co/QJ9DYp8JuV
Dr. John Cush RheumNow ( View Tweet)
Pt Reported Outcomes in axSpA or PsA may be interpreted differently if fibromyalgia is present. ASDAS-CRP, & duration of lumbar AM stiffness were not affected by FM, yet FM significantly caused higher scores in axSpA or PsA all assessments https://t.co/v8wFzIVxUr https://t.co/eIXRoktYja
Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/TIdCtJjF21 https://t.co/UE0nGbESDB
Links:
Dr. John Cush RheumNow ( View Tweet)
Guselkumab maintenance dose is 100 mg sc q8wks. GUIDE ph 3b trial treated 297 PSO super responders (PASI <3) w/ q8wk or extended q16wk GUS & demonstrated noninferiority of q16 wk dosing w/ disease control (91.9 vs 92.6%) https://t.co/31DPTmcVD2 https://t.co/qHMsyYCH4J
Dr. John Cush RheumNow ( View Tweet)
Cohorts of 100 compared PsO/PsA pts to controls. Psoriatic pts had significantly more cases of polyneuropathy than controls (RR ~20), but the significance was lost when corrected for frequent comorbidities that cause neuropathy https://t.co/ujPlgmISUc https://t.co/aNLaJMDhvM
Dr. John Cush RheumNow ( View Tweet)
Harris poll of 1286 #PsA pts (52% female) shows gender differences in perception. Women had different presenting Sxs, more joint tenderness, skin PSO, and enthesitis, and greater impact on well-being. Treating female PsA is different! https://t.co/H3PQkKCg9n https://t.co/FmwhgkVJ7J
Dr. John Cush RheumNow ( View Tweet)
Digital Self Screening for Arthritis Diagnosis
A new study evaluates patient use of a mobile AI–based symptom checker for diagnoses, but demonstrated only modest accuracy when applied to a cohort of patients with joint symptoms.
https://t.co/YLkheDOrdI https://t.co/MFMEYifP3W
Dr. John Cush RheumNow ( View Tweet)
2001-2004 NHANES population study shows 28% report hx of erectile dysfunction (ED) & 19% w/ arthritis. Having arthritis was assoc w/ 4 fold higher ED risk; mostly in #OA (OR=1.11), RA (OR=1.03). https://t.co/L2LhEPH9DY https://t.co/yLhVmLw7nt
Dr. John Cush RheumNow ( View Tweet)
Best Rheumatologists (7.19.2024)
Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.
https://t.co/2Tkdat6CXv https://t.co/1lOfbgNZvn
Dr. John Cush RheumNow ( View Tweet)
Prospective cohort study from 474 055 participants in UK Biobank, finds long-term exposure to air pollutants, NO2 etc, assoc w/ a 19% to 47% increased risk incident psoriasis. Air pollution and genetic predisposition also significantly incr incident PsO https://t.co/ogX81ybU3l https://t.co/Mvd6tAj2j6
Dr. John Cush RheumNow ( View Tweet)
IL-17 inhibitor Brodalumab is not often talked about, but its approved for PsO & PsA. German study of 227 PsO w/ 37 PsA pts Rx w/ BRO - good, rapid response by 3 mos. 1 year drug survival rate was 76.2%, (mean discontinuation=8.3 mos. https://t.co/4byFoc96Zs https://t.co/sPomX0s8aa
Dr. John Cush RheumNow ( View Tweet)
Later onset PsO may benefit from earlier PsA screening. Cohort study of 384 Psoriasis pts. Older PsO onset assoc w/ shorter interval from PsO to PsA. PsO onset at 42.6 yrs had a 62% shorter interval & OR 4.56 to have PsA w/in 6 mos. https://t.co/DSiYs88MFa https://t.co/reID2wvLiu
Dr. John Cush RheumNow ( View Tweet)
